ArticleNature food2024
Engineered plants provide a photosynthetic platform for the production of diverse human milk oligosaccharides.
Article in Nature food, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A Comprehensive Review of Fucosylated Human Milk Oligosaccharides: Biological Functions, Production Technologies, and Safety Regulation With Commercial Translation in Infant Nutrition.Comprehensive reviews in food science and food safety · 2026Review
- Comparative Analysis of Oligosaccharide and Phenolic Profiles in White and Red Grape Pomace from California.Molecules (Basel, Switzerland) · 2026Article
- Human milk: insights on cell composition, organoids and emerging applications.Pediatric research · 2026Review
- Computationally guided enzyme engineering for regioselective synthesis of fucosylated human milk oligosaccharides.Applied microbiology and biotechnology · 2026Article
- Lacto-N-tetraose biosynthesis from lactose via metabolically rewired Escherichia coli.Metabolic engineering · 2026Article
- Metabolic Engineering ofChem & bio engineering · 2026Article
- Biomimetic Mammary Gland Organoid-on-a-Chip for Producing Selected Human Milk Components.Research (Washington, D.C.) · 2026Article
- Protein engineering strategies to optimise recombinant product synthesis and accumulation in Nicotiana benthamiana.Plant biotechnology journal · 2026Review
- Genetically Reprogramming Crops and Rhizobacteria for Nutritional Iron Biofortification.ACS synthetic biology · 2025Review
- Navigating the challenges of engineering composite specialized metabolite pathways in plants.The Plant journal : for cell and molecular biology · 2025Review
- Article
- A comprehensive framework for the production of plant-based molecules.Nature food · 2024Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Human milk oligosaccharides (HMOs) are a diverse class of carbohydrates which support the health and development of infants. The vast health benefits of HMOs have made them a commercial target for microbial production; however, producing the approximately 200 structurally diverse HMOs at scale has proved difficult. Here we produce a diversity of HMOs by leveraging the robust carbohydrate anabolism of plants. This diversity includes high-value and complex HMOs, such as lacto-N-fucopentaose I. HMOs produced in transgenic plants provided strong bifidogenic properties, indicating their ability to serve as a prebiotic supplement with potential applications in adult and infant health. Technoeconomic analyses demonstrate that producing HMOs in plants provides a path to the large-scale production of specific HMOs at lower prices than microbial production platforms. Our work demonstrates the promise in leveraging plants for the low-cost and sustainable production of HMOs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.